Victory Square Technologies (VST.C) gets the Brazilian nod to launch their Leishmaniasis rapid test

Victory Square Health/Safetest, a subsidiary of Victory Square Technologies (VST.C), has gotten the nod from the Brazilian Ministry of Agriculture, Livestock and Food Supply (MAPA) for marketing, selling and distributing their Leishmaniasis rapid test in Brazil, and also to export to Mercosur countries (Argentina, Paraguay, Uruguay and Venezuela) today, according to a press release.

Leishmaniasis is a parasitic disease that affects humans and dogs in Southern Europe, Central America, South America, Mexico and the Middle East. The numbers range from 4-12 million presently infected over 98 countries. About 2 million new cases happen every year, and if they were left undetected and untreated would cause disability and death. The disease is common in Asia, Africa, South and Central America, and southern Europe. The company entered into a sales and distribution contract for the Leishmaniasis test with Ecodiagnostica of Brazil.

“Our Leishmaniasis test is just one of many tests currently approved or in our development pipeline. Our global distribution and sales network has grown exponentially with our numerous approvals of our Safetest Covid-19 testing products. These new avenues and new partnership agreements will provide this test and others with easy access to key markets,” said Felipe Peixoto, CEO of Victory Square Health.

VS Health has been around since 2016 and was created to develop personalized medicine and technology solutions including diagnostic tests in support of patient care and the improvement of health outcomes. The Leishmaniasis Rapid Test, developed along with the Federal University of Minas Gerais (UFMG), is their first product. Safetest also called upon the university’s expertise to develop antibody-based tests and a robust research and development system of diagnostic kits for Hansen’s Disease, Brucellosis, HLV and blood samples screening tests.

VS Health developed and verified the performance of its Leishmaniasis diagnostic test with results that presently exceed available tests with greater sensitivity and specificity in acquiring a correct diagnosis in both humans and canines.

—Joseph Morton

More on

0 0 votes
Article Rating
Notify of
Inline Feedbacks
View all comments